SCHEMBL3097328

SCHEMBL3097328

CCN(C(=O)C(CCc1ccc(OC)cc1)C(=O)NS(=O)(=O)C=Cc1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.45
RECQL P46063 1/20 0.45
ALDH1A1 P00352 4/20 0.44
LMNA P02545 3/20 0.44
TRPM8 Q7Z2W7 4/20 0.43
MMP1 P03956 5/20 0.40
MMP2 P08253 5/20 0.40
MMP3 P08254 4/20 0.40
PDE4A P27815 3/20 0.40
PDE4B Q07343 3/20 0.40
PDE4C Q08493 3/20 0.40
PDE4D Q08499 3/20 0.40
PPARG P37231 1/20 0.39
NFE2L2 Q16236 1/20 0.39
POLB P06746 1/20 0.39
MMP9 P14780 2/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PLAAT3 P53816 1/20 0.38
PLAAT5 Q96KN8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3097317 1.00 GAA (0.45) GAARECQLALDH1A1LMNATRPM8
SCHEMBL3096338 0.91 POLB (0.40) GAAALDH1A1MMP2MMP3POLB
SCHEMBL3092640 0.91 ALDH1A1 (0.46) GAARECQLALDH1A1LMNATRPM8
SCHEMBL3092630 0.91 ALDH1A1 (0.46) GAARECQLALDH1A1LMNATRPM8
SCHEMBL3079178 0.90 POLB (0.40) GAARECQLALDH1A1LMNAPOLB
SCHEMBL3079172 0.90 POLB (0.40) GAARECQLALDH1A1LMNAPOLB
SCHEMBL3097810 0.90 POLB (0.42) GAARECQLALDH1A1POLBSMN1; SMN2
SCHEMBL3097822 0.90 POLB (0.42) GAARECQLALDH1A1POLBSMN1; SMN2
SCHEMBL3100032 0.88 ALDH1A1 (0.43) ALDH1A1LMNATRPM8MMP1MMP2
SCHEMBL3097204 0.87 POLB (0.37) GAAALDH1A1MMP1PPARGPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 GAA 272/4885RECQL 3794/4885ALDH1A1 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.